Skip to main content
SpringerLink
Log in

Pharmakologie des Harntraktes

  • Chapter
Urodynamik

Zusammenfassung

Die Darstellung der Pharmakologie des Harntraktes im Rahmen einer Abhandlung über Urodynamik hat mehrere Gründe. So gelingt die Interpretation urodynamischer Kurven nur mit dem Wissen um physiologische Funktionsabläufe und mögliche Krankheitsursachen. Diese sind nur zum Teil anatomisch, häufig aber auch neurologisch, zellularmetabolisch oder rezeptorvermittelt bedingt. Darüber hinaus hat die Pharmakologie bei urodynamischen Spezialuntersuchungen wie z.B. dem Carbachol-Test bereits Einzug in die Funktionsdiagnostik gehalten. Schließlich ist die Behandlung der drangassoziierten Blasenfunktionsstörung bis heute eine pharmakologische Domäne geblieben und ein Blick auf zukünftige pharmakologische Entwicklungen eröffnet auch für die Stressinkontinenz hoffnungsvolle Perspektiven.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersson KE (2000a) New roles for muscarinic receptors in the pathophysiology of lower urinary tract symptoms. BJU Int 86(S2): 36–43

    PubMed  CAS  Google Scholar 

  2. Andersson KE (2000b) Treatment of overactive bladder: other drug mechanisms. Urology 55 (5A Suppl): 51–57; discussion 59

    Article  PubMed  CAS  Google Scholar 

  3. Araki I (1994) Inhibitory postsynaptic currents and the effects of GABA on visually identified sacral parasympathetic preganglionic neurons in neonatal rats. J Neurophysiol 72(6): 2903–2910

    PubMed  CAS  Google Scholar 

  4. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J12(4): 1693–1703

    Google Scholar 

  5. Chancellor MB, de Groat WC (1999) Intravesical capsaicin and resinife-ratoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162(1): 3–11

    Article  PubMed  CAS  Google Scholar 

  6. Clifford GM, Farmer RD (2000) Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 38(1): 2–19

    Article  PubMed  CAS  Google Scholar 

  7. de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50 (6A Suppl): 36–52; discussion 53–56

    Article  PubMed  Google Scholar 

  8. de Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Ann Rev Pharmacol Toxicol 41:691–721

    Article  Google Scholar 

  9. Dmochowski RR, Appell RA (2000) Advancements in pharmacologic management of the overactive bladder. Urology 56 (6 Suppl 1): 41–49

    Article  PubMed  CAS  Google Scholar 

  10. Doren M (1998) Urogenital aging-creation of improved awareness. Am J Obstet Gynecol 178(5): S254–S256

    Article  PubMed  CAS  Google Scholar 

  11. Downie JW (1999) Pharmacological manipulation of central micturition circuitry. Curr Opin Investig Drugs 1:231–239

    CAS  Google Scholar 

  12. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139(5): 919–922

    PubMed  CAS  Google Scholar 

  13. Harriss DR, Marsh KA, Birmingham AT, Hill SJ (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154(3): 1241–1245

    Article  PubMed  CAS  Google Scholar 

  14. Hegde SS, Choppin A, Bonhaus D et al.(1997) Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120 (8): 1409–1418

    Article  PubMed  CAS  Google Scholar 

  15. Hills CJ, Winter SA, Balfour JA (1998) Tolterodine. Drugs 55(6): 813–820; discussion 821–822

    Article  PubMed  CAS  Google Scholar 

  16. Hjalmas K (1999) Desmopressin treatment: current status. Scand J Urol Nephrol Suppl 202:70–72

    Article  PubMed  CAS  Google Scholar 

  17. Kakizaki H, Yoshiyama M, de Groat WC (1996) Role of NMDA and AMPA glutamatergic transmission in spinal c-fos expression after urinary tract irritation. Am J Physiol 270(5 Pt 2): R990–996

    PubMed  CAS  Google Scholar 

  18. Kenny BA, Miller AM, Williamson IJ, JOC, Chalmers DH, Naylor AM (1996) Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 118(4): 871–878

    Article  PubMed  CAS  Google Scholar 

  19. Kuiper GG, Gustafsson JA (1997) The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410(1): 87–90

    Article  PubMed  CAS  Google Scholar 

  20. Ozawa H, Chancellor MB, Jung SY, et al. (1999) Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol 162(6): 2211–2216

    Article  PubMed  CAS  Google Scholar 

  21. Parczyk K, Schneider MR (1996) The future of antihormone therapy: innovations based on an established principle. J Cancer Res Clin Oncol 122(7): 383–396

    Article  PubMed  CAS  Google Scholar 

  22. Pitsikas N (2000) Duloxetine Eli Lilly &Co.Curr Opin Investig Drugs 1(1): 116–121

    PubMed  CAS  Google Scholar 

  23. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3): 413–492

    PubMed  CAS  Google Scholar 

  24. Robertson G, Rittig S, Kovacs L, Gaskill MB, Zee P, Nanninga J (1999) Pathophysiology and treatment of enuresis in adults. Scand J Urol Nephrol Suppl 202:36–38; discussion 38–39

    Article  PubMed  CAS  Google Scholar 

  25. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botu-linum-A toxin as a treatment of detrusor-sphincterdyssynergia:a prospective study in 24 spinal cord injury patients. J Urol 155(3): 1023–1029

    Article  PubMed  CAS  Google Scholar 

  26. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164(3 Pt 1): 692–697

    Article  PubMed  CAS  Google Scholar 

  27. Schwinn DA (2001) The role of alpha-1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 88 (Suppl 2): 27–34; discussion 49–50

    Article  PubMed  CAS  Google Scholar 

  28. Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE (2001) Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 20:105–113

    Article  PubMed  CAS  Google Scholar 

  29. Somogyi GT, Tanowitz M, Zernova G, de Groat WC (1996) M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J Physiol 496 (Pt 1):245–254

    PubMed  CAS  Google Scholar 

  30. Testa R, Guameri L, Poggesi E, et al. (1999) Effect of several 5-hydro-xytryptamine(IA) receptor ligands on the micturition reflex in rats: comparison with WAY 100635. J Pharmacol ExpTher 290(3): 1258–1269

    CAS  Google Scholar 

  31. Truss MC, Stief CG, Uckert S et al. (2000) Initial clinical experience with the selective phosphodiesterase-l isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18(6):439–443

    Article  PubMed  CAS  Google Scholar 

  32. Truss MC, Stief CG, Uckert S et al. (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19(5): 344–350

    Article  PubMed  CAS  Google Scholar 

  33. Wheeler MA, Smith SD, Saito N, Foster HE Jr, Weiss RM (1997) Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. J Urol 158(6):2045–2050

    Article  PubMed  CAS  Google Scholar 

  34. Yokoyama O, Yoshiyama M, Namiki M, de Groat WC (2000) Role of the forebrain in bladder overactivity following cerebral infarction in the rat. Exp Neurol 163(2):469–476

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Hampel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Thüroff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hampel, C., Thüroff, J.W. (2004). Pharmakologie des Harntraktes. In: Urodynamik. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10727-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10727-0_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10728-7

  • Online ISBN: 978-3-662-10727-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation